Nuvation Bio Delivers Transformational 2025: Strong Q4 Results, Rapid IBTROZI® Adoption, and Promising Pipeline Progress

Key Highlights for Investors

• Blockbuster Launch for IBTROZI® (taletrectinib): 216 new U.S. patient starts in Q4 2025, totaling 432 since the mid-June launch, with an adoption rate approximately six times higher than recent ROS1 TKI launches. IBTROZI is quickly establishing itself as a new standard of care for advanced ROS1+ non-small cell lung cancer (NSCLC).
• Major Global Partnership: On January 11, 2026, Nuvation Bio entered an exclusive licensing and collaboration deal with Eisai to commercialize taletrectinib in Europe and multiple other territories outside the U.S., China, and Japan, expanding global reach and revenue potential.
• Strong Financial Position: The company ended 2025 with \$529.2 million in cash, cash equivalents, and marketable securities, supporting continued growth and pipeline investments.
• Milestone Payments: Received a \$25 million milestone from Nippon Kayaku for reimbursement pricing in Japan; taletrectinib added to China’s National Reimbursement Drug List, effective January 1, 2026.
• Pipeline Advancement: Published positive Phase 2 results for safusidenib in IDH1-mutant glioma (ORR of 44%, 88% progression-free at 24 months), with the pivotal Phase 3 SIGMA trial underway.
• Revenue Growth: Generated \$15.7 million in U.S. product revenue for Q4 and \$24.7 million for the full year, reflecting rapid commercial uptake.
• Reduced Net Loss: For 2025, net loss improved to \$204.6 million (\$0.60/share) from \$567.9 million (\$2.11/share) in 2024, mainly due to higher revenue and lower R&D charges.
• Increased Operating Expenses: Significant increases in R&D and SG&A expenses reflect investments in commercial infrastructure, pipeline expansion, and one-time compensation charges tied to FDA approval milestones.

Detailed Business Update

IBTROZI® (taletrectinib) – Rapid Market Penetration and Global Expansion

• IBTROZI®, a next-generation ROS1 inhibitor, achieved 432 new patient starts since its U.S. launch in June 2025. This outpaces prior ROS1 TKI launches by roughly six-fold, signaling overwhelming confidence among oncologists and patients.
• Significant milestone events included:
  • January 2026: Exclusive licensing and collaboration agreement with Eisai for extensive global markets outside Nuvation’s direct reach.
  • Q4 2025: \$25 million milestone payment from Nippon Kayaku for Japanese reimbursement pricing.
  • China: Taletrectinib included in the National Reimbursement Drug List, effective January 2026, positioning the drug for further commercial expansion.
  • October 2025: Pivotal TRUST-II study data presented at ESMO Congress demonstrated an 80% confirmed overall response rate in patients previously treated with entrectinib, reinforcing the drug’s robust efficacy profile.
• Regulatory and clinical programs are advancing globally, with multiple registrational studies ongoing, including the pivotal TRUST-I, TRUST-II, and TRUST-IV studies, as well as a confirmatory Phase 3 trial (TRUST-III) in China.

Safusidenib – Advancing Brain Cancer Therapy

• December 2025: Publication of positive Phase 2 results in Neuro-Oncology for safusidenib in grade 2 IDH1-mutant glioma. The drug demonstrated a 44% objective response rate and 88% progression-free survival at 24 months in chemotherapy/radiotherapy-naïve patients.
• Following favorable FDA interactions, the pivotal SIGMA (G203) Phase 3 trial is now active, evaluating safusidenib maintenance in high-risk and high-grade IDH1-mutant gliomas, including a new exploratory cohort in grade 3 oligodendroglioma.
• First patient enrolled in the global SIGMA study in October 2025.

Financial Performance and Guidance

• Balance Sheet: \$529.2 million in cash, cash equivalents, and marketable securities as of December 31, 2025, provides ample runway for continued commercial and R&D investments.
• Revenue: Q4 2025 total revenue was \$41.87 million (including product and collaboration/license revenue); full-year revenue was \$62.9 million, up sharply from \$7.87 million in 2024.
• Expenses:
  • R&D expenses rose to \$115.1 million for 2025 (from \$99.1 million in 2024), reflecting increased clinical trial activity and headcount.
  • SG&A expenses doubled to \$151.6 million (from \$69.2 million), driven by commercial launch costs and milestone-related compensation.
  • 2024 saw a one-time \$425.1 million charge for acquired in-process R&D from the AnHeart Therapeutics acquisition, which did not recur in 2025.
• Net Loss: Q4 2025 net loss was \$36.6 million (\$0.11/share). For 2025, net loss was \$204.6 million (\$0.60/share), a significant improvement from the prior year due to rising revenues and absence of large one-time charges.
• Share Count: Weighted average shares outstanding for 2025 were 341.5 million (up from 268.8 million in 2024).

Important Shareholder and Price-Sensitive Considerations

• Commercial Success of IBTROZI: The rapid adoption rate and global expansion agreements position IBTROZI as a potential blockbuster, which could re-rate Nuvation’s valuation if sustained.
• Global Partnerships: The Eisai deal opens major new markets, expanding the addressable patient population and potential royalty streams.
• Pipeline Momentum: Positive safusidenib data and ongoing pivotal trials could provide additional catalysts, especially in high-unmet-need brain cancers.
• Financial Strength: The strong cash position gives Nuvation flexibility for further pipeline advancement, business development, or potential M&A.
• Expense Increases: While necessary for growth, the sharp rise in operating expenses may pressure margins in the near term, though offset by revenue growth and pipeline value creation.
• Regulatory and Safety Risks: As with all oncology launches, post-marketing requirements, safety surveillance, and competitive developments remain risks to watch.

Product and Pipeline Safety Information

• IBTROZI Safety: Key warnings include risks of hepatotoxicity, ILD/pneumonitis, QTc prolongation, hyperuricemia, myalgia/CPK elevation, skeletal fractures, embryo-fetal toxicity, and photosensitivity. The most common adverse reactions were diarrhea (64%), nausea (47%), vomiting (43%), dizziness (22%), rash (22%), constipation (21%), and fatigue (20%).
• Drug Interactions: Concomitant use with certain CYP3A inhibitors/inducers and QTc-prolonging drugs should be avoided. Use of gastric acid-reducing agents should be managed carefully.
• Fertility and Lactation: IBTROZI may impair fertility and should not be used during breastfeeding.
• Pediatric Use: Safety and efficacy in pediatric patients have not been established.

Conference Call Information

Nuvation Bio will host a conference call and webcast on March 2, 2026, at 4:30 pm ET to discuss fourth quarter and full year 2025 results and provide business updates. Investors and the general public can access the webcast via the investor relations section of the company’s website or dial in using the provided numbers.

About Nuvation Bio

Nuvation Bio is a global oncology company focused on innovative therapies for challenging cancers, with a pipeline including IBTROZI® (taletrectinib), safusidenib, and novel drug-drug conjugates. The company was founded by industry veteran Dr. David Hung, also known for founding Medivation, Inc.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Forward-looking statements in this article are subject to risks and uncertainties, including but not limited to clinical development, regulatory approvals, commercialization success, and competitive market dynamics. Investors should review all relevant filings and disclosures before making investment decisions.

View Nuvation Bio Inc. Historical chart here